AIDS 2014: iPrEx OLE Confirms PrEP Works, but Many Don't Take It [VIDEO]

alt

The open-label extension of the iPrEx study found that Truvada pre-exposure prophylaxis (PrEP) was highly The open-label extension of the iPrEx study found that Truvada pre-exposure prophylaxis (PrEP) was highly effective among gay men who took it regularly to prevent HIV, but many did not do so, researchers reported this week at the 20th International AIDS Conference in Melbourne.

No one who took at least 4 doses of tenofovir/emtricitabine per week became infected. However, a substantial proportion of participants stopped taking their pills or did so irregularly, leading to a lower overall efficacy rate of 49%.

Robert Grant speaks at AIDS 2014 press briefing, July 22, 2014

iPrEx principal investigator Robert Grant from the Gladstone Institutes in San Francisco summarized the key findings from the study at an AIDS 2014 media briefing before his presentation.

"Interest and uptake of PrEP is high," Grant said. "We discovered that men and trans women who were at high risk for acquiring HIV were more likely to participate in the open-label extension, were more likely to take up PrEP, and were more likely to adhere to it."

See also: AIDS 2014: iPrEx OLE Shows PrEP Effectuveness Is 100% for Those Taking 4 or More Doses per Week

7/23/14

Reference

RM Grant, PL Anderson, V McMahan, et al. Results of the iPrEx open-label extension (iPrEx OLE) in men and transgender women who have sex with men: PrEP uptake, sexual practices, and HIV incidence. 20th International AIDS Conference (AIDS 2014). Melbourne, July 20-25, 2014. Abstract TUAC0105LB.